REDWOOD CITY, CALIF, Jan. 4, 2013 (GLOBE NEWSWIRE) -- Pearl Therapeutics Inc. today announced that Chuck Bramlage, the Company's president and CEO will be providing a corporate and clinical update at the 31st annual J.P. Morgan Healthcare Conference in San Francisco, CA. Mr. Bramlage's presentation will include discussion of the Company's inhaled, fixed-dose combination bronchodilator product candidate, PT003, and its monotherapy components, PT001 and PT005. Pearl's presentation will take place on Wednesday, January 9, 2013 at 4:00pm Pacific Time.
About Pearl Therapeutics
Pearl Therapeutics is a privately held company developing combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease and asthma. Pearl is rapidly advancing a pipeline of products including PT003, an inhaled, fixed-dose combination bronchodilator product comprised of a long-acting muscarinic antagonist (LAMA) and a long-acting beta‑2 agonist (LABA) delivered via a metered dose inhaler (HFA MDI); and PT010, a triple-combination product that combines the LAMA and LABA components of PT003 with an inhaled corticosteroid (ICS) for twice-daily administration from an HFA MDI for the treatment of severe COPD. Both PT003 and PT010 are developed with Pearl's proprietary porous particle co‑suspension technology, which allows the formulation of multiple products in the MDI format, with highly stable, robust and aerodynamically efficient drug delivery. Founded in 2006, Pearl Therapeutics is privately held and backed by 5AM Ventures, Clarus Ventures, New Leaf Ventures and Vatera Healthcare. For more information, please visit www.pearltherapeutics.com.
Source: Pearl Therapeutics